Cancer Immunosurveillance by T Cells
- PMID: 30635090
- DOI: 10.1016/bs.ircmb.2018.08.001
Cancer Immunosurveillance by T Cells
Abstract
Cancer immunotherapy is based on the ability of the immune system to recognize tumors as foreign tissue. The idea of cancer immunosurveillance was first conceived over a century ago but remained controversial through much of the 20th century. In the past few decades, however, the field has progressed rapidly, and the concept of tumor immunosurveillance is now well established. With this chapter, we provide a historical background of immunosurveillance, the concept of immunoediting, and the role of different T-cell subsets in the tumor microenvironment. We also discuss the relationship between immune checkpoints, tumor antigens, T cell receptor repertoire, and immunosurveillance. Finally, we comment on the future of immunotherapy as it relates to T cell immunosurveillance.
Keywords: Antigen specificity; Cancer immunosurveillance; Immune checkpoint blockade; Immunoediting; T cell repertoire fitness.
Copyright © 2019 Elsevier Inc. All rights reserved.
Similar articles
-
On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation.Sci Transl Med. 2015 Mar 25;7(280):280sr1. doi: 10.1126/scitranslmed.3010274. Sci Transl Med. 2015. PMID: 25810313 Review.
-
Translation of cancer immunotherapy from the bench to the bedside.Adv Cancer Res. 2019;143:1-62. doi: 10.1016/bs.acr.2019.03.001. Epub 2019 May 2. Adv Cancer Res. 2019. PMID: 31202357 Review.
-
Challenges and prospects of immunotherapy as cancer treatment.Biochim Biophys Acta. 2007 Sep;1776(1):108-23. doi: 10.1016/j.bbcan.2007.07.003. Epub 2007 Jul 17. Biochim Biophys Acta. 2007. PMID: 17720322 Review.
-
The immune system and cancer evasion strategies: therapeutic concepts.J Intern Med. 2016 Jun;279(6):541-62. doi: 10.1111/joim.12470. Epub 2016 Jan 8. J Intern Med. 2016. PMID: 26748421 Review.
-
Leprosy as a model to understand cancer immunosurveillance and T cell anergy.J Leukoc Biol. 2016 Jul;100(1):47-54. doi: 10.1189/jlb.5RU1215-537RR. Epub 2016 Apr 22. J Leukoc Biol. 2016. PMID: 27106673 Review.
Cited by
-
Trial watch: IDO inhibitors in cancer therapy.Oncoimmunology. 2020 Jun 14;9(1):1777625. doi: 10.1080/2162402X.2020.1777625. Oncoimmunology. 2020. PMID: 32934882 Free PMC article. Review.
-
Trial Watch: experimental TLR7/TLR8 agonists for oncological indications.Oncoimmunology. 2020 Jul 21;9(1):1796002. doi: 10.1080/2162402X.2020.1796002. Oncoimmunology. 2020. PMID: 32934889 Free PMC article. Review.
-
Combination of Nanomaterials in Cell-Based Drug Delivery Systems for Cancer Treatment.Pharmaceutics. 2021 Nov 8;13(11):1888. doi: 10.3390/pharmaceutics13111888. Pharmaceutics. 2021. PMID: 34834304 Free PMC article. Review.
-
Evolution of the clinical-stage hyperactive TcBuster transposase as a platform for robust non-viral production of adoptive cellular therapies.Mol Ther. 2024 Jun 5;32(6):1817-1834. doi: 10.1016/j.ymthe.2024.04.024. Epub 2024 Apr 16. Mol Ther. 2024. PMID: 38627969
-
Redefining innate natural antibodies as important contributors to anti-tumor immunity.Elife. 2021 Oct 5;10:e69713. doi: 10.7554/eLife.69713. Elife. 2021. PMID: 34608861 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous
